Cargando…

Twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter?

OBJECTIVES: To study the long-term results of the treatment of patients with vaginal cancer and to examine whether there are any differences in diagnostic and survival rates between urban and rural patients. METHODS: The data of 70 patients with primary vaginal cancer treated at NN Alexandrov Nation...

Descripción completa

Detalles Bibliográficos
Autores principales: Matylevich, Olga P, Trukhan, Hanna V, Zubets, Olga I, Mavrichev, Siarhei A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426020/
https://www.ncbi.nlm.nih.gov/pubmed/34567252
http://dx.doi.org/10.3332/ecancer.2021.1267
_version_ 1783749958927646720
author Matylevich, Olga P
Trukhan, Hanna V
Zubets, Olga I
Mavrichev, Siarhei A.
author_facet Matylevich, Olga P
Trukhan, Hanna V
Zubets, Olga I
Mavrichev, Siarhei A.
author_sort Matylevich, Olga P
collection PubMed
description OBJECTIVES: To study the long-term results of the treatment of patients with vaginal cancer and to examine whether there are any differences in diagnostic and survival rates between urban and rural patients. METHODS: The data of 70 patients with primary vaginal cancer treated at NN Alexandrov National Cancer Centre of Belarus from 2000 to 2019 were included. The median age was 64 years (range = 56–75). Morphology in 91.4% (64/70) of the cases was squamous cell cancer, in 7.1% (5/70) it was adenocarcinoma and in 1.4% (1/70) it was adenosquamous carcinoma. In total, there were 31 patients from urban and 39 from rural areas. The groups were comparable in age (61 versus 67, p = 0.104), morphology (p = 0.188) and distribution of stages: stage I in 7 and 10 patients (22.6% and 25.6%, respectively; p = 0.999), stage II in 14 and 16 patients (45.1% and 41.0%, respectively; p = 0.810), stage III in 6 and 6 patients (19.4% and 15.4%, respectively; p = 0.754) and stage IV in 4 and 7 patients (12.9% and 18.0%, respectively; p = 0.744). RESULTS: The median follow-up time was 33 months (range = 1–220). A total of 42 women died: 28 from progression of vaginal cancer and 14 from other diseases. Overall survival (OS) was 31.9 ± 6.8%, median survival was 41 months (95% CI = 0.0–105.3). Disease-specific survival (DSS) for the entire group was 54.5 ± 6.8%; median was not reached. The overall survival rate of urban women was 44.8 ± 10.6% and for rural it was 22.5 ± 8.2% (p = 0.142); DSS was 57.6 ± 10.5% and 53.0 ± 8.4% (p = 0.448), respectively. CONCLUSION: DSS rate was 54.0 ± 6.8% and the OS rate did not exceed 31.9 ± 6.8%. Rural residence was not associated with late stage at diagnosis or receipt of treatment.
format Online
Article
Text
id pubmed-8426020
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-84260202021-09-24 Twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter? Matylevich, Olga P Trukhan, Hanna V Zubets, Olga I Mavrichev, Siarhei A. Ecancermedicalscience Clinical Study OBJECTIVES: To study the long-term results of the treatment of patients with vaginal cancer and to examine whether there are any differences in diagnostic and survival rates between urban and rural patients. METHODS: The data of 70 patients with primary vaginal cancer treated at NN Alexandrov National Cancer Centre of Belarus from 2000 to 2019 were included. The median age was 64 years (range = 56–75). Morphology in 91.4% (64/70) of the cases was squamous cell cancer, in 7.1% (5/70) it was adenocarcinoma and in 1.4% (1/70) it was adenosquamous carcinoma. In total, there were 31 patients from urban and 39 from rural areas. The groups were comparable in age (61 versus 67, p = 0.104), morphology (p = 0.188) and distribution of stages: stage I in 7 and 10 patients (22.6% and 25.6%, respectively; p = 0.999), stage II in 14 and 16 patients (45.1% and 41.0%, respectively; p = 0.810), stage III in 6 and 6 patients (19.4% and 15.4%, respectively; p = 0.754) and stage IV in 4 and 7 patients (12.9% and 18.0%, respectively; p = 0.744). RESULTS: The median follow-up time was 33 months (range = 1–220). A total of 42 women died: 28 from progression of vaginal cancer and 14 from other diseases. Overall survival (OS) was 31.9 ± 6.8%, median survival was 41 months (95% CI = 0.0–105.3). Disease-specific survival (DSS) for the entire group was 54.5 ± 6.8%; median was not reached. The overall survival rate of urban women was 44.8 ± 10.6% and for rural it was 22.5 ± 8.2% (p = 0.142); DSS was 57.6 ± 10.5% and 53.0 ± 8.4% (p = 0.448), respectively. CONCLUSION: DSS rate was 54.0 ± 6.8% and the OS rate did not exceed 31.9 ± 6.8%. Rural residence was not associated with late stage at diagnosis or receipt of treatment. Cancer Intelligence 2021-07-15 /pmc/articles/PMC8426020/ /pubmed/34567252 http://dx.doi.org/10.3332/ecancer.2021.1267 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Matylevich, Olga P
Trukhan, Hanna V
Zubets, Olga I
Mavrichev, Siarhei A.
Twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter?
title Twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter?
title_full Twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter?
title_fullStr Twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter?
title_full_unstemmed Twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter?
title_short Twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter?
title_sort twenty years’ experience of primary vaginal cancer treatment at one cancer centre: does residence status matter?
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426020/
https://www.ncbi.nlm.nih.gov/pubmed/34567252
http://dx.doi.org/10.3332/ecancer.2021.1267
work_keys_str_mv AT matylevicholgap twentyyearsexperienceofprimaryvaginalcancertreatmentatonecancercentredoesresidencestatusmatter
AT trukhanhannav twentyyearsexperienceofprimaryvaginalcancertreatmentatonecancercentredoesresidencestatusmatter
AT zubetsolgai twentyyearsexperienceofprimaryvaginalcancertreatmentatonecancercentredoesresidencestatusmatter
AT mavrichevsiarheia twentyyearsexperienceofprimaryvaginalcancertreatmentatonecancercentredoesresidencestatusmatter